June 4, 2017 02:41 PM EDT
R&D
Pharma

PD-L1 check­point play­er Mer­ck KGaA dives in­to next-gen work with F-star col­lab­o­ra­tion

John Carroll

Editor & Founder

CHICA­GO — Not all the biotech news on can­cer drugs this past week­end is di­rect­ly re­lat­ed to the big AS­CO con­fab in Chica­go. Cam­bridge, UK-based F …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times